Lih‐Jen Su

1.2k total citations
26 papers, 975 citations indexed

About

Lih‐Jen Su is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Biotechnology. According to data from OpenAlex, Lih‐Jen Su has authored 26 papers receiving a total of 975 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Biotechnology. Recurrent topics in Lih‐Jen Su's work include Bladder and Urothelial Cancer Treatments (5 papers), Synthesis and bioactivity of alkaloids (4 papers) and Cancer, Lipids, and Metabolism (4 papers). Lih‐Jen Su is often cited by papers focused on Bladder and Urothelial Cancer Treatments (5 papers), Synthesis and bioactivity of alkaloids (4 papers) and Cancer, Lipids, and Metabolism (4 papers). Lih‐Jen Su collaborates with scholars based in United States, China and Poland. Lih‐Jen Su's co-authors include Thomas W. Flaig, Gail S. Harrison, Rajesh Agarwal, L. Michael Glodé, Daniel L. Gustafson, Frances Crighton, Joseph A. Zirrolli, A. Scott Pierson, L. Michael Glode and Ian H. Maxwell and has published in prestigious journals such as Advanced Materials, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Lih‐Jen Su

25 papers receiving 954 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lih‐Jen Su United States 14 459 359 160 154 137 26 975
Martin Wurm Austria 12 364 0.8× 67 0.2× 233 1.5× 85 0.6× 88 0.6× 20 861
Adel Kardosh United States 19 424 0.9× 142 0.4× 419 2.6× 135 0.9× 284 2.1× 75 1.4k
Hye-Jin Jang South Korea 13 599 1.3× 406 1.1× 152 0.9× 346 2.2× 51 0.4× 19 1.0k
Hongzhuan Yin China 19 539 1.2× 164 0.5× 115 0.7× 253 1.6× 46 0.3× 35 915
Wei‐Hao Sun China 17 483 1.1× 209 0.6× 128 0.8× 179 1.2× 196 1.4× 41 1.1k
Qinghua Yao China 21 653 1.4× 118 0.3× 314 2.0× 220 1.4× 111 0.8× 62 1.2k
Feiya Yang China 19 645 1.4× 285 0.8× 211 1.3× 332 2.2× 59 0.4× 70 1.5k
Yi Chen China 20 612 1.3× 208 0.6× 123 0.8× 230 1.5× 38 0.3× 103 1.2k
Marcia Pomplun United States 14 497 1.1× 58 0.2× 220 1.4× 115 0.7× 81 0.6× 18 838

Countries citing papers authored by Lih‐Jen Su

Since Specialization
Citations

This map shows the geographic impact of Lih‐Jen Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lih‐Jen Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lih‐Jen Su more than expected).

Fields of papers citing papers by Lih‐Jen Su

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lih‐Jen Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lih‐Jen Su. The network helps show where Lih‐Jen Su may publish in the future.

Co-authorship network of co-authors of Lih‐Jen Su

This figure shows the co-authorship network connecting the top 25 collaborators of Lih‐Jen Su. A scholar is included among the top collaborators of Lih‐Jen Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lih‐Jen Su. Lih‐Jen Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lee, Jin Gyun, Alex C. Hughes, Lih‐Jen Su, et al.. (2025). Soft Extrudable Dendritic Particles with Nanostructured Tendrils for Local Adhesion and Drug Release to Bladder Cancers. Advanced Materials. 37(38). e2505231–e2505231.
2.
Lam, Elaine T., et al.. (2023). Preclinical evaluation of teleglenastat (CB-839) in prostate cancer.. Journal of Clinical Oncology. 41(6_suppl). 378–378. 3 indexed citations
3.
Kessler, Elizabeth R., Lih‐Jen Su, Dexiang Gao, et al.. (2018). Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer. Integrative Cancer Therapies. 17(4). 1103–1108. 6 indexed citations
4.
Cho, Suehyun K., et al.. (2018). Multifunctional nanoclusters of NaYF4:Yb3+,Er3+ upconversion nanoparticle and gold nanorod for simultaneous imaging and targeted chemotherapy of bladder cancer. Materials Science and Engineering C. 97. 784–792. 38 indexed citations
5.
Yang, Xiaoping, Lih‐Jen Su, Francisco G. La Rosa, et al.. (2017). The Antineoplastic Activity of Photothermal Ablative Therapy with Targeted Gold Nanorods in an Orthotopic Urinary Bladder Cancer Model. Bladder Cancer. 3(3). 201–210. 12 indexed citations
6.
Flaig, Thomas W., Lih‐Jen Su, Zhiyong Zhang, et al.. (2017). Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade. Oncotarget. 8(34). 56051–56065. 73 indexed citations
7.
Yang, Xiaoping, Francisco G. La Rosa, Jerome Schaack, et al.. (2013). Simultaneous Activation of Kras and Inactivation of p53 Induces Soft Tissue Sarcoma and Bladder Urothelial Hyperplasia. PLoS ONE. 8(9). e74809–e74809. 14 indexed citations
8.
Li, Yuan, Xiaoping Yang, Lih‐Jen Su, & Thomas W. Flaig. (2011). Pazopanib Synergizes with Docetaxel in the Treatment of Bladder Cancer Cells. Urology. 78(1). 233.e7–233.e13. 21 indexed citations
9.
Flaig, Thomas W., Michael Glodé, Daniel L. Gustafson, et al.. (2010). A study of high‐dose oral silybin‐phytosome followed by prostatectomy in patients with localized prostate cancer. The Prostate. 70(8). 848–855. 148 indexed citations
10.
Flaig, Thomas W., Lih‐Jen Su, Caroline E. McCoach, et al.. (2009). Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose‐ and sequence‐dependent manner. British Journal of Urology. 103(12). 1729–1737. 25 indexed citations
11.
Flaig, Thomas W., Lih‐Jen Su, Gail S. Harrison, Rajesh Agarwal, & L. Michael Glodé. (2007). Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. International Journal of Cancer. 120(9). 2028–2033. 50 indexed citations
12.
Flaig, Thomas W., Daniel L. Gustafson, Lih‐Jen Su, et al.. (2006). A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Investigational New Drugs. 25(2). 139–146. 264 indexed citations
13.
Flaig, Thomas W., et al.. (2006). The effect of ultrasonic irradiation on doxorubicin-induced cytotoxicity in three human bladder cancer cell lines. Ultrasonics. 46(1). 68–73. 12 indexed citations
14.
Marchbank, Angela, Lih‐Jen Su, Patrick Walsh, et al.. (2003). The CUSP ΔNp63α isoform of human p63 is downregulated by solar-simulated ultraviolet radiation. Journal of Dermatological Science. 32(1). 71–74. 12 indexed citations
15.
Dellavalle, Robert P., Patrick Walsh, Angela Marchbank, et al.. (2002). CUSP/p63 expression in basal cell carcinoma. Experimental Dermatology. 11(3). 203–208. 15 indexed citations
16.
Dellavalle, Robert P., et al.. (2001). CUSP/p63 expression in rat and human tissues. Journal of Dermatological Science. 27(2). 82–87. 35 indexed citations
17.
Lee, Lela A., Patrick Walsh, Lih‐Jen Su, et al.. (1999). Characterization of an Autoantigen Associated With Chronic Ulcerative Stomatitis: The CUSP Autoantigen is a Member of the p53 Family1. Journal of Investigative Dermatology. 113(2). 146–151. 48 indexed citations
18.
19.
Walsh, Patrick, Andrew J. Dorner, Richard C. Duke, Lih‐Jen Su, & L. Michael Glode. (1995). Macrophage Colony-Stimulating Factor Complementary DNA: a Candidate for Gene Therapy in Metastatic Melanoma. JNCI Journal of the National Cancer Institute. 87(11). 809–816. 11 indexed citations
20.
Erickson, Paul F., Ian H. Maxwell, Lih‐Jen Su, Marc Baumann, & L. Michael Glode. (1990). Sequence of cDNA for rat cystathionine γ-lyase and comparison of deduced amino acid sequence with related Escherichia coli enzymes. Biochemical Journal. 269(2). 335–340. 112 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martin Wurm Breakdown of academic impact, for papers by Adel Kardosh Breakdown of academic impact, for papers by Hye-Jin Jang Breakdown of academic impact, for papers by Hongzhuan Yin Breakdown of academic impact, for papers by Wei‐Hao Sun Breakdown of academic impact, for papers by Qinghua Yao Breakdown of academic impact, for papers by Feiya Yang Breakdown of academic impact, for papers by Yi Chen Breakdown of academic impact, for papers by Marcia Pomplun
Rankless by CCL
2026